Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immunocore Holdings (IMCR) Long-Term Deferred Tax (2019 - 2025)

Immunocore Holdings' Long-Term Deferred Tax history spans 3 years, with the latest figure at $14.3 million for Q3 2025.

  • For Q3 2025, Long-Term Deferred Tax rose 13.19% year-over-year to $14.3 million; the TTM value through Sep 2025 reached $14.3 million, up 13.19%, while the annual FY2024 figure was $14.8 million, 34.79% up from the prior year.
  • Long-Term Deferred Tax for Q3 2025 was $14.3 million at Immunocore Holdings, up from $14.1 million in the prior quarter.
  • Across five years, Long-Term Deferred Tax topped out at $14.8 million in Q4 2024 and bottomed at $10.1 million in Q2 2024.
  • The 3-year median for Long-Term Deferred Tax is $13.4 million (2024), against an average of $12.8 million.
  • The largest YoY upside for Long-Term Deferred Tax was 39.22% in 2025 against a maximum downside of 13.19% in 2025.
  • A 3-year view of Long-Term Deferred Tax shows it stood at $11.0 million in 2023, then surged by 34.79% to $14.8 million in 2024, then decreased by 3.09% to $14.3 million in 2025.
  • Per Business Quant, the three most recent readings for IMCR's Long-Term Deferred Tax are $14.3 million (Q3 2025), $14.1 million (Q2 2025), and $14.4 million (Q1 2025).